Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hutton

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
Journal of Neurology|January 15, 2025
Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease managementBlake D Colman, Paul G Sanfilippo, Anthony Fok, et al.
Advanced Drug Delivery Reviews|August 19, 2023
Long-acting microneedle formulationsLalitkumar K Vora, Akmal H Sabri, Yara Naser, et al.
Frontiers in Neurology|June 15, 2026
Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia PacificCharles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, et al.
International Journal of Pharmaceutics|August 29, 2024
Transdermal delivery of bisphosphonates using dissolving and hydrogel-forming microarray patches: Potential for enhanced treatment of osteoporosisAnastasia Ripolin, Fabiana Volpe-Zanutto, Akmal H Sabri, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|November 1, 1996
Preserving medical schools' academic mission in a competitive marketplaceA M Fogelman, L D Goode, B L Behrens, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Neurology|February 3, 2017
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MSRichard A Nash, George J Hutton, Michael K Racke, et al.
Pharmacology & Therapeutics|March 23, 2021
The chemistry and toxicology of vapingEmily Bonner, Yvonne Chang, Emerson Christie, et al.
American Journal of Human Genetics|December 29, 2005
Discriminating power of localized three-dimensional facial morphologyPeter Hammond, Tim J Hutton, Judith E Allanson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline dataJ A Cohen, P A Calabresi, S Chakraborty, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
Journal of Neurology|January 15, 2025
Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease managementBlake D Colman, Paul G Sanfilippo, Anthony Fok, et al.
Advanced Drug Delivery Reviews|August 19, 2023
Long-acting microneedle formulationsLalitkumar K Vora, Akmal H Sabri, Yara Naser, et al.
Frontiers in Neurology|June 15, 2026
Delphi consensus on the real-world application of the updated diagnostic and treatment guidelines for migraine in Asia PacificCharles Hua Chiang Siow, Shengyuan Yu, Surat Tanprawate, et al.
International Journal of Pharmaceutics|August 29, 2024
Transdermal delivery of bisphosphonates using dissolving and hydrogel-forming microarray patches: Potential for enhanced treatment of osteoporosisAnastasia Ripolin, Fabiana Volpe-Zanutto, Akmal H Sabri, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|November 1, 1996
Preserving medical schools' academic mission in a competitive marketplaceA M Fogelman, L D Goode, B L Behrens, et al.
Multiple Sclerosis and Related Disorders|June 5, 2020
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 yearsJiwon Oh, Anat Achiron, Elisabeth G Celius, et al.
Neurology|February 3, 2017
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MSRichard A Nash, George J Hutton, Michael K Racke, et al.
Pharmacology & Therapeutics|March 23, 2021
The chemistry and toxicology of vapingEmily Bonner, Yvonne Chang, Emerson Christie, et al.
American Journal of Human Genetics|December 29, 2005
Discriminating power of localized three-dimensional facial morphologyPeter Hammond, Tim J Hutton, Judith E Allanson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline dataJ A Cohen, P A Calabresi, S Chakraborty, et al.
Pageof 37